Ozempic without the side effects? New drug touted as weight loss game changer
There's no doubt that GLP-1 drugs like Ozempic have been revolutionary — not just for people who want to lower their blood sugar and lose weight but for those who want to control other cravings as well.
Unfortunately, sometimes these benefits come with unsightly downsides such as tooth decay, a droopy face or mouth, a saggy butt and hair loss.
While many of those side effects are due to rapid weight loss — rather than the drugs themselves — the medications are known to cause icky gastrointestinal issues.
People on drugs like Ozempic have complained about some unpleasant side effects, including tooth decay, a droopy face or mouth, a saggy butt and hair loss.
K KStock – stock.adobe.com
Now, a groundbreaking new drug has shown some of the same promise in melting belly fat — without making your stomach churn.
This week in the journal Cell, researchers unveiled a drug — developed by the Sweden biotechnology company Atrogi AB — based on a type of special molecule.
While GLP-1s mimic the GLP-1 hormone the body naturally produces after eating to suppress appetite, this new drug activates metabolism in skeletal muscle.
In a Phase I clinical trial involving 25 people with Type 2 diabetes and 48 healthy humans, the drug was successful at improving blood sugar levels and weight — without those pesky GLP-1 side effects.
Since most GLP-1s are injectables, the fact that this medication comes in tablet form could be groundbreaking to trypanophobes.
Since most GLP-1s are injectables, the fact that this medication comes in tablet form could also be groundbreaking to anyone who is afraid of needles.
í¢í°í½í íÅí¸í°í¸íâíÅ½í° – stock.adobe.com
'This drug represents a completely new type of treatment and has the potential to be of great importance for patients with Type 2 diabetes and obesity,' Shane C. Wright, assistant professor at the Department of Physiology and Pharmacology at Karolinska Institutet in Stockholm, said in a statement.
'Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections.'
Wright noted that the drug can be used 'as a stand-alone treatment and in combination with GLP-1 drugs.'
This can be a game changer for people who are micro-dosing drugs like Ozempic due to the sky-high costs.
It could also be impactful now that the Food and Drug Administration has cracked down on Ozempic copycats, potentially slimming options for consumers who have come to rely on budget-friendly alternatives.
Finally, researchers say the drug can boost weight loss without negatively influencing muscle mass or overworking the heart — both crucial longevity markers.
'Our results point to a future where we can improve metabolic health without losing muscle mass,' said Tore Bengtsson, a professor at the Department of Molecular Bioscience at Wenner-Gren Institute in Stockholm.
'Muscles are important in both Type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
19 hours ago
- New York Times
Is It Wrong to Push Ozempic on My Spouse?
My husband's lifestyle is very sedentary, with minimal exercise (20 to 60 minutes a week), though he does eat a largely healthy diet. I've watched him struggle with his weight over the 15 years we've been together, cycling through various approaches to diet and exercise. Even when he succeeds in losing weight, it always comes back, and now he seems to have given up. As we both approach 50, I worry that his B.M.I., which is 30, and his B.R.I. (body roundness index, a measure of abdominal fat) are high (he can't even button some of his shirts around the middle), which could lead to other health issues. I've already tried encouraging him to move more and eat better, but I can't schedule every one of my workouts for us to exercise together, and he dislikes some of the routines I do, anyway. He's also very sensitive about his weight. Is it wrong for me to try to get him to take Ozempic? I'm hoping that losing weight will help boost his energy levels, which might lead to more self-care. I know it's not my body, and I'm not his doctor, but as his wife I also know it will fall to me to care for him if health issues arise. — Name Withheld From the Ethicist: It's natural to worry about the health of someone you love — especially as the years accumulate and the lines between caring for yourself and caring for your partner begin to blur. Long-term relationships involve a particular kind of vigilance: You notice the wince, the shortened breath, the unbuttoned shirt. This isn't control; it's love in the form of everyday attention. Obesity really is correlated with health problems, and if your husband could lose weight sustainably, his life might improve in ways that matter. Historically, weight loss has been a story of perpetual disappointment — diets abandoned, exercise routines that peter out, New Year's resolutions that start wobbling the following evening when it becomes clear that celery sticks are an imperfect substitute for chocolates. GLP-1 drugs, such as Ozempic, have helped many people break that cycle. Still, even sound advice can land wrong if it touches a nerve. If your husband is sensitive about his weight, the real challenge isn't knowing what's best; it's finding a way to talk about it that feels loving, not critical. Try to keep the focus on the prospect of his feeling fitter and on your hope for more good years ahead. Maybe suggest he talk to his doctor — not as a directive but as a way to explore options. You're not pushing him to 'fix' himself; you're looking out for him. If it turns out to be a difficult conversation all the same? Loving someone can mean risking that discomfort — for the sake of all the days you haven't yet lived together. Want all of The Times? Subscribe.
Yahoo
20 hours ago
- Yahoo
BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, BioMarin Pharmaceutical Inc. presented new 5-year data from its Phase 3 GENEr8-1 trial at the 33rd Congress of the International Society on Thrombosis and Haemostasis/ISTH in Washington, D.C., which took place from June 21 to 25. The data reinforced the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) as a gene therapy for severe hemophilia A. The GENEr8-1 trial is the longest and largest hemophilia gene therapy study to date, and demonstrated sustained Factor VIII (FVIII) expression and durable bleed control 5 years after a single treatment with ROCTAVIAN. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. FVIII activity remained consistent with previously reported results. Importantly, no new safety signals were observed over the 5-year study period. Across all 134 participants who received ROCTAVIAN in the study, there were no cases of FVIII inhibitors or thromboembolic events, and no treatment-related malignancies were observed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions internationally. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Solar-Powered Slug Steals Chloroplasts and Stores Them for Emergency Food
'Solar-powered' sea slugs have specialized depots in their cells that store photosynthetic equipment looted from algae, a study reports. These depots provide just the right chemical environment to keep the stolen apparatus, called chloroplasts, alive and working to turn sunlight into nutrients. 'It was the wildest thing that we had seen,' says study co-author Nicholas Bellono, a biologist at Harvard University in Cambridge, Massachusetts. The authors also found that, in lean times, the slugs can raid these compartments to consume chloroplasts. The compartment 'is basically like a moving refrigerator of chloroplasts where, after a period of starvation, the slugs can switch from storage to consumption to survive', Bellono says. [Sign up for Today in Science, a free daily newsletter] The findings were published in Cell. Scientists discovered decades ago that certain species of sea slug store chloroplasts from the algae they eat, a diet that can turn the slugs bright green. But no one understood how the slugs keep these foreign organelles alive without the support of the rest of the algal cell. Bellono and his team added chemical tags to proteins newly made by the slugs' own cells. They found that most of the proteins in a slug's chloroplasts were made by the slug — not by the original algae. That meant the slug was helping to maintain the chloroplasts. When the scientists looked at the chloroplasts under a microscope, they found that the organelles were housed in special compartments in the slugs' guts. Each compartment was surrounded by a membrane that tested positive for markers typically found in cellular structures called phagosomes, which fuse with other structures called lysomes to digest unneeded organelles. The researchers named this structure the kleptosome, after a Greek word that means to steal. The team also found that these organelles contained ion channels — receptors that convert chemical messages into electrical signals. Among them is one called P2X4, which opens in response to the presence of ATP, an energy-carrying molecule produced during photosynthesis. When Bellono and his team blocked this channel in slugs' kleptosomes, oxygen production from photosynthesis dropped, showing that the kleptosome is actively involved in keeping the chloroplasts functioning. Having discovered the existence of the kleptosome, the researchers wondered whether it helps the slugs to resist starvation. They compared the solar-powered slug Elysia crispata with Aplysia californica, a non-photosynthetic slug that lacks kleptosomes. Aplysia died after three to four weeks without food, whereas Elysia could survive for up to four months. Yet, after four weeks, the Elysia slugs lost their green colour, turned orange — just as leaves do in autumn — and stopped photosynthesizing. Microscopy revealed that the Elysia's kleptosomes had begun fusing with lysosomes and that the colour change was caused by the degradation of the chloroplast. The study is 'remarkable,' says cell biologist Elena Oancea at Brown University in Providence, Rhode Island. Studying the molecular and cellular processes of creatures as small as sea slugs is extremely challenging, she says. 'It takes a lot of courage to do that.' The discovery of the kleptosome could help to answer broader questions about organelle evolution and other cellular processes that we don't understand yet, Oancea says. All life is built on cells, she adds: 'It's the basic principle of nature.' This article is reproduced with permission and was first published on June 25, 2025.
